LeonaBio (LONA) awards 300,000 stock options to general counsel
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
LeonaBio, Inc. reported that its General Counsel and Chief Compliance Officer, Mark Worthington, received a grant of stock options covering 300,000 shares of common stock. The options have an exercise price of $9.54 per share and expire on April 8, 2036.
The award was classified as a grant or other acquisition of a derivative security, with 300,000 options held directly after the transaction. According to the grant terms, the underlying shares are scheduled to vest monthly over 48 months, subject to his continued service as a provider under LeonaBio’s 2026 Equity Incentive Plan.
Positive
- None.
Negative
- None.
Insider Trade Summary
1 transaction reported
Mixed
1 txn
Insider
Worthington Mark
Role
GENERAL COUNSEL and CCO
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (Right to Buy) | 300,000 | $0.00 | -- |
Holdings After Transaction:
Stock Option (Right to Buy) — 300,000 shares (Direct)
Footnotes (1)
- [object Object]
Key Figures
Stock options granted: 300,000 options
Exercise price: $9.54 per share
Expiration date: April 8, 2036
+1 more
4 metrics
Stock options granted
300,000 options
Grant of stock options to General Counsel and CCO
Exercise price
$9.54 per share
Exercise price of granted stock options
Expiration date
April 8, 2036
Option expiration for 300,000 granted options
Vesting schedule
48 months monthly
Options vest monthly over 48 months, subject to continued service
Key Terms
Stock Option (Right to Buy), derivative security, 2026 Equity Incentive Plan, Service Provider
4 terms
Stock Option (Right to Buy) financial
"security_title: "Stock Option (Right to Buy)""
derivative security financial
"The award was classified as a grant or other acquisition of a derivative security"
A derivative security is a financial contract whose value comes from the price or performance of something else, such as a stock, bond, commodity, or market index. For investors it acts like an insurance policy or a wager: it can be used to protect against losses, lock in prices, or amplify gains and losses, so it can change a portfolio’s risk and potential return without owning the underlying asset directly.
2026 Equity Incentive Plan financial
"as defined in the Issuer's 2026 Equity Incentive Plan"
Service Provider financial
"subject to the optionee continuing to be a Service Provider"
FAQ
What insider transaction did LeonaBio (LONA) report for Mark Worthington?
LeonaBio reported that General Counsel and Chief Compliance Officer Mark Worthington received a grant of 300,000 stock options. These options give him the right to buy common shares at a fixed price and represent a compensation-related equity award rather than an open-market stock purchase or sale.
How many LeonaBio (LONA) stock options were granted in this Form 4?
The filing shows a grant of 300,000 stock options to Mark Worthington. Each option corresponds to one share of LeonaBio common stock, giving rights over 300,000 underlying shares if exercised according to the plan’s vesting and exercise terms in the future.
What is the exercise price and expiration date of the LeonaBio (LONA) options?
The stock options have an exercise price of $9.54 per share and expire on April 8, 2036. This means Worthington can choose to buy shares at $9.54, if vested, any time before the 2036 expiration date, subject to the plan’s conditions.
How do the LeonaBio (LONA) options granted to Mark Worthington vest?
The 300,000 stock options vest in monthly installments over 48 months from the grant date. Vesting requires Worthington to continue as a “Service Provider” under LeonaBio’s 2026 Equity Incentive Plan through each monthly vesting date for the relevant portion to become exercisable.